SF3B1 and myelofibrosis: The results of this study raise the question whether patients with CMML-RS/SF3B1 and monocytosis <1.0 x109/L should be properly classified as CMML or should be rather classified as MDS with RS/SF3B1 mutation and relative monocytosis similar to what we observe in myelofibrosis when it presents with monocytosis (35).